Fruquintinib plus FOLFIRI for second-line metastatic colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs, fruquintinib and FOLFIRI chemotherapy, as a second treatment option for people with metastatic colorectal cancer. It is designed for patients who have already received one prior treatment containing oxaliplatin, fluoropyrimidine, and bevacizumab.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic colorectal cancer that has spread to other parts of your body and your tumor is measurable.
- You have had only one prior treatment for this cancer that included oxaliplatin, a fluoropyrimidine, and bevacizumab.
- Your cancer does not have certain genetic features (MSI-H or BRAF V600 mutation).
- You are at least 18 years old and able to care for yourself (ECOG score 0 to 2).
- You have not had FOLFIRI or irinotecan before, and you haven't had surgery within the past 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies fruquintinib combined with serplulimab (an immune therapy) for advanced colorectal cancer that has spread and is no longer responding to standard treatments. It may help by slowing the cancer’s growth and improving outcomes after the usual options have been tried.
This trial tests a drug called fruquintinib, given alone or with a chemotherapy infusion directly into your liver, for people whose colorectal cancer has spread to the liver and has stopped responding to standard treatments. It aims to find a new option for patients with limited cancer outside the liver.
This trial is testing a new combination of two oral cancer drugs (fruquintinib and S-1) in people with metastatic colorectal cancer who have already had at least one prior chemotherapy. The goal is to see if this combination helps shrink or slow the growth of tumors.
This trial tests whether adding TAS-102 to fruquintinib works better than fruquintinib alone for people with advanced colorectal cancer that has stopped responding to other treatments.
This trial tests whether the combination of fruquintinib with chemotherapy (trifluridine/tipiracil) works as well as or better than the current standard of bevacizumab with the same chemotherapy for advanced colorectal cancer that has spread. It is for patients who have already had several lines of treatment and are looking for new options.
This trial compares two different drug combinations for people with colorectal cancer that has spread and has already been through one round of chemotherapy. One combination uses a newer targeted pill (fruquintinib) while the other uses a standard targeted medicine (bevacizumab), both with chemotherapy. The goal is to see which approach works better as a second-line treatment.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.